These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38262300)

  • 41. Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.
    Li J; Jia S; Zhang W; Qiu F; Zhang Y; Gu X; Xue J
    BMC Surg; 2015 Jun; 15():79. PubMed ID: 26123412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
    Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
    Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sentinel lymph node biopsy alone without axillary lymph node dissection--follow up of sentinel lymph node negative breast cancer patients.
    Reitsamer R; Peintinger F; Prokop E; Menzel C; Cimpoca W; Rettenbacher L
    Eur J Surg Oncol; 2003 Apr; 29(3):221-3. PubMed ID: 12657230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Axillary sentinel node biopsy after neoadjuvant chemotherapy.
    Ozmen V; Unal ES; Muslumanoglu ME; Igci A; Canbay E; Ozcinar B; Mudun A; Tunaci M; Tuzlali S; Kecer M
    Eur J Surg Oncol; 2010 Jan; 36(1):23-9. PubMed ID: 19931375
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
    Damin AP; Zancan M; Melo MP; Biazus JV
    Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
    Boughey JC; Ballman KV; Le-Petross HT; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Feliberti EC; Hunt KK
    Ann Surg; 2016 Apr; 263(4):802-7. PubMed ID: 26649589
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group.
    Tausch C; Konstantiniuk P; Kugler F; Reitsamer R; Roka S; Pöstlberger S; Haid A;
    Ann Surg Oncol; 2008 Dec; 15(12):3378-83. PubMed ID: 19097267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy.
    Boneti C; Korourian S; Bland K; Cox K; Adkins LL; Henry-Tillman RS; Klimberg VS
    J Am Coll Surg; 2008 May; 206(5):1038-42; discussion 1042-4. PubMed ID: 18471751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients.
    Canavese G; Tinterri C; Carli F; Garrone E; Spinaci S; Della Valle A; Barbieri E; Marrazzo E; Bruzzi P; Dozin B
    Eur J Surg Oncol; 2021 Aug; 47(8):1920-1927. PubMed ID: 33972144
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
    Kuehn T; Bauerfeind I; Fehm T; Fleige B; Hausschild M; Helms G; Lebeau A; Liedtke C; von Minckwitz G; Nekljudova V; Schmatloch S; Schrenk P; Staebler A; Untch M
    Lancet Oncol; 2013 Jun; 14(7):609-18. PubMed ID: 23683750
    [TBL] [Abstract][Full Text] [Related]  

  • 52. De-escalating axillary management after neoadjuvant chemotherapy in breast cancer: The ratio of positive sentinel lymph nodes matters.
    Aragón-Sánchez S; Sánchez-Bayona R; López-Marín L; Ciruelos-Gil E; Parrilla-Rubio L; Zaragoza-Ballester P; Galindo-Izquierdo A; García-Chapinal B; Álvaro-Valiente L; Oliver-Pérez MR
    Surg Oncol; 2024 Jun; 54():102062. PubMed ID: 38531288
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
    Breslin TM; Cohen L; Sahin A; Fleming JB; Kuerer HM; Newman LA; Delpassand ES; House R; Ames FC; Feig BW; Ross MI; Singletary SE; Buzdar AU; Hortobagyi GN; Hunt KK
    J Clin Oncol; 2000 Oct; 18(20):3480-6. PubMed ID: 11032588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.
    Fan YJ; Li JC; Zhu DM; Zhu HL; Zhao Y; Zhu XB; Wu G; Bai TT
    BMC Surg; 2023 Jul; 23(1):209. PubMed ID: 37495945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of survival outcomes for axillary surgery extent based on intraoperative sentinel lymph node biopsy result after neoadjuvant chemotherapy for breast cancer.
    Chun JW; Kim J; Chung IIY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
    Breast Cancer Res Treat; 2021 Jun; 187(3):647-655. PubMed ID: 33966181
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are the ACOSOG Z0011 Trial Findings Being Applied to Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?
    Kantor O; Pesce C; Liederbach E; Wang CH; Winchester DJ; Yao K
    Breast J; 2017 Sep; 23(5):554-562. PubMed ID: 28295828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
    Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
    Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer.
    Nagar H; Wietek N; Goodall RJ; Hughes W; Schmidt-Hansen M; Morrison J
    Cochrane Database Syst Rev; 2021 Jun; 6(6):CD013021. PubMed ID: 34106467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study.
    Coufal O; Zapletal O; Gabrielová L; Fabian P; Schneiderová M
    Rozhl Chir; 2018; 97(12):551-557. PubMed ID: 30646734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.